Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002504 · ClinicalTrials.gov registry record · Phase 2
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002504: Completed Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
NCT00002504 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002504, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-2 and interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 plus interferon alfa in treating adults with metastatic cancer.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interferon alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-08 |
| Est. Completion | 1999-02 |
| Phase | Phase 2 |
What the finished NCT00002504 record still lists
NCT00002504 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00002504 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002504 about?
NCT00002504 is a clinical study titled "Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-2 and interferon alfa may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of inter...
What is the current status of trial NCT00002504?
This trial is currently completed. It is a Phase 2 study. The study started on 1992-08. Estimated completion is 1999-02.
What interventions are being tested in trial NCT00002504?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002504?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia